How to manage an 84-year-old female with a past medical history (PMH) of congestive heart failure (CHF), hyperlipidemia (HLD), atrial fibrillation (A FIB), coronary artery disease (CAD), chronic kidney disease stage 3b (CKDIIIb), and diabetes mellitus type 2 (DMII), presenting with dyspnea, cough, and fatigue, and recent positive COVID-19 test, with laboratory results showing hyponatremia and impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Diuretic-Induced Hyponatremia in an 84-Year-Old with Heart Failure and CKD Stage 3b

Continue holding both furosemide and metolazone until sodium normalizes above 135 mEq/L, maintain fluid restriction and high-protein diet, and when diuresis is eventually needed, restart furosemide alone at a reduced dose (40 mg daily or twice daily) while permanently discontinuing metolazone. 1, 2

Immediate Management: Continue Current Approach

Your current management is appropriate and should be continued:

  • Hold all diuretics (both furosemide and metolazone) until sodium normalizes above 135 mEq/L, as the patient has clear diuretic-induced hyponatremia from excessive self-administration (120 mg furosemide daily plus metolazone). 1, 2

  • Continue fluid restriction and high-protein diet as these are first-line interventions for hypervolemic hyponatremia in heart failure patients. 1

  • Monitor sodium every 24-48 hours until stable and normalized, which aligns with your current BMP monitoring schedule. 2

  • The patient is not volume overloaded on exam (no pulmonary edema on CXR, normal oxygen saturation, diminished but not congested breath sounds), so aggressive diuresis is not indicated. 1

Critical Context: CKD Stage 3b Considerations

This patient's renal function significantly impacts diuretic management:

  • With CKD stage 3b (eGFR 33, creatinine 1.54), loop diuretics like furosemide remain effective, but thiazide-type diuretics (metolazone/Zaroxolyn) lose effectiveness at creatinine clearance <40 mL/min and increase risk of electrolyte abnormalities. 2

  • Metolazone should be permanently discontinued in this patient given her CKD stage 3b and propensity for severe hyponatremia. 2

  • The combination of loop diuretic plus metolazone markedly enhances risk of electrolyte depletion, which clearly occurred here. 1

When to Restart Diuretics

Restart furosemide only when:

  • Sodium is ≥135 mEq/L (currently trending up from 120→122→124→125→127, so continue monitoring). 2

  • Clinical evidence of volume overload develops (pulmonary edema, significant peripheral edema, worsening dyspnea with hypoxia). 1

Dosing strategy when restarting:

  • Start with furosemide 40 mg once or twice daily (significantly lower than her self-administered 120 mg daily), not the previous home dose of 40 mg BID plus metolazone. 2

  • Never restart metolazone given her CKD stage 3b and severe hyponatremia episode. 2

  • Check electrolytes and renal function within 2-4 days of restarting diuretics. 2

Addressing the Underlying Trigger

The patient's COVID-19 infection likely triggered:

  • Increased fluid intake or decreased oral intake leading to relative volume changes. 3, 4

  • Her self-medication with triple-dose furosemide (120 mg daily) plus metolazone was inappropriate and caused the hyponatremia, not actual volume overload. 5

Guideline-Directed Medical Therapy (GDMT) Continuation

Continue her current heart failure medications (sacubitril-valsartan/Entresto, apixaban) as she is hemodynamically stable:

  • Blood pressure 115-130/61-78 mmHg is acceptable and not contraindicated for GDMT. 1

  • Sertraline was appropriately held as SSRIs can contribute to hyponatremia. 5

  • Do not hold Entresto unless she becomes hypotensive (<90 mmHg systolic) or develops acute kidney injury. 1, 6

Vasopressin Antagonists: Not Indicated

While the 2013 ACC/AHA guidelines mention vasopressin antagonists (tolvaptan, conivaptan) for persistent severe hyponatremia:

  • This patient is asymptomatic (no cognitive symptoms, confusion, or seizures). 1

  • Her sodium is improving with conservative management (fluid restriction, holding diuretics). 1

  • Vasopressin antagonists are Class IIb (may be considered) only for persistent severe hyponatremia with cognitive symptoms despite water restriction. 1

  • They did not improve mortality in heart failure patients and have unknown long-term safety. 1

Monitoring Plan Going Forward

  • Check BMP every 24-48 hours until sodium >135 mEq/L. 2

  • Once stable, monitor electrolytes and renal function every 3-6 months. 2

  • Patient and family education is critical: she must not self-adjust diuretic doses, and should contact her provider if she feels volume overloaded. 5

  • Consider nephrology consultation if sodium fails to improve or if complex diuretic management is needed given her CKD stage 3b. 2, 6

Key Pitfalls to Avoid

  • Do not restart metolazone in this patient with CKD stage 3b—it is ineffective and dangerous at her level of renal function. 2

  • Do not restart diuretics at previous doses—she was overdosed at 120 mg furosemide daily plus metolazone. 1, 2

  • Do not use vasopressin antagonists in asymptomatic patients with improving sodium on conservative management. 1

  • Do not hold Entresto unnecessarily—continue GDMT unless hemodynamically unstable. 1, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Hyponatremia in Patients with Impaired Renal Function

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

COVID-19 and cardiovascular diseases.

Journal of cardiology, 2020

Research

Hyponatremia-Inducing Drugs.

Frontiers of hormone research, 2019

Research

Management of Heart Failure Patient with CKD.

Clinical journal of the American Society of Nephrology : CJASN, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.